Home Stocks Lupin Ltd

Lupin Ltd

The live share price of Lupin Ltd (LUPIN) as on 03 May 6:31am is ₹1,658 from NSE/BSE.

LUPIN NSE

₹1,658 ▲0.63% (10.35)

As on May 03, 2024 12:01 PM IST

How do you feel today about Lupin Ltd?

Bearish or

Bullish

Bearish or

Bullish

Key Metrics

PE Ratio

41.88

PB Ratio

5.98

Dividend Yield

0.24%

Sector PB

5.96

Sector PE

52.69

Sector Div Yld

0.57%

Dividend Yield

Dividend per share for the most recent financial year divided by the close price

About

Sector

Health Care

Industry

Pharmaceuticals

Market Cap

Midcap, ₹75,011 Cr

Lupin Limited is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.

The following charts display the financial performance of the Lupin Ltd (LUPIN) stock, including the year-on-year Income Statement , Balance Sheet , Cash Flow Statement and Shareholding pattern.

Furthermore, under the Peers section, you can find stocks that are similar to Lupin Ltd (LUPIN), and their live stock price and performance at a glance. Click on any peer stock to navigate to that stock’s live price page.

✅ If you’re new to investing in the stock market, and/or are unsure about your investment options, you can explore smallcases.

A smallcase is a readymade stock/ETF portfolio (also known as a stock basket) that is based on an investment idea, theme or strategy. Examples of popular smallcases include All Weather Investing , Equity and Gold , Top 100 Stocks , Green Energy and Value & Momentum.

All smallcases are created and managed by SEBI-registered investment experts.

To invest in smallcases, all you need is a demat/trading account. You retain complete ownership of the smallcase’s constituent stocks or ETFs, as they are directly credited to your broking account. You can choose from over 500+ smallcases across 180+ smallcase managers to start your investment journey.

Sector

Health Care

Industry

Pharmaceuticals

Market Cap

Midcap, ₹75,011 Cr

Financials

Income Statement

(INR)		Y/Y Change
Revenue	16,792 Cr	+1.06%
Operating Expense	1,972 Cr	-44.95%
Net Income	430 Cr	-128.15%
Net Profit Margin	2.56%	-127.83%
Earning Per Share	9	-128.11%
EBITDA	1,871 Cr	+335.97%

Balance sheet

(INR)		Y/Y Change
Cash & short-term Inv	1,732 Cr	-9.77%
Total Assets	22,800 Cr	+5.31%
Total Liabilities	10,257 Cr	+8.78%
Total Equity	12,542 Cr	+2.63%
Shares Outstanding	45.5 Cr	+0.12%
Price to Book	2.35	-17.44%
Return on Assets	1.94%	-128.61%
Return on Capital	7.9 Cr	-178.53%

Cash Flows

(INR)		Y/Y Change
Net Income	430 Cr	-128.15%
Cash from Operations	1,897 Cr	+416.52%
Cash from Investing	-1,286 Cr	-199.58%
Cash from Financing	-337 Cr	-78.55%
Net Change in Cash	273 Cr	+213.25%
Free Cash Flow	397 Cr	-173.94%

Shareholding Pattern

Total Promoter Holding

47.01%

Unpledged

Foreign Institutions

18.28%

Foreign Institutions

Retail & Others

6.94%

Retail & Others

Other Parties

Other Domestic Institutions

10.95%

Insurance Firms

Others

Mutual Funds

16.82%

Mutual Funds

Peers

SUNPHARMA

Sun Pharmaceutical Industries Ltd

PE Ratio

40.47

1Y Return

▲56.11%

CIPLA

Cipla Ltd

PE Ratio

30.48

1Y Return

▲54.74%

DRREDDY

Dr Reddy's Laboratories Ltd

PE Ratio

19.76

1Y Return

▲27.01%

ZYDUSLIFE

Zydus Lifesciences Ltd

PE Ratio

32.26

1Y Return

▲84.46%

Latest News

Lupin Receives USFDA Nod For Generic Eye Medication

1 week ago on Bloomberg Quint

Change since news ▼-INF%

Lupin has obtained USFDA approval to market a generic eye medication, Loteprednol Etabonate ophthalmic suspension, 0.5%, for treating certain eye conditions.

Lupin - New Drugs Approvals Will Boost Future Prospects: Axis Securities

1 week ago on Bloomberg Quint

Change since news ▼-INF%

Niche product approvals and a strong pipeline of new drugs could drive revenue/profit after tax compound annual growth rate by 10%/19.5% over FY24E-FY26E.

Lupin Launches Generic Drug In US Market

2 weeks ago on Bloomberg Quint

Change since news ▼-INF%

The company’s product is a generic equivalent of Astellas Pharma Global Development, Inc’s Myrbetriq extended-release tablets, it added.

FAQs on Lupin Ltd

How to buy Lupin Ltd stocks?

You can easily buy the stocks/shares of Lupin Ltd (LUPIN) through either a broker or a financial institution by opening a Demat & Trading account online via smallcase.

What is the Share Price of Lupin Ltd?

The stock price of Lupin Ltd as on 03 May 2024 is ₹1,658

What is the 52-week High and Low of Lupin Ltd?

The 52-week high and low of Lupin Ltd (LUPIN) is ₹1,704.25 and ₹702.4.

What is the PE and PB ratio of Lupin Ltd?

The P/E (price-to-earnings) and P/B (price-to-book) ratios of Lupin Ltd are 41.88 and 5.98 respectively.

What are the peers or stocks similar to Lupin Ltd?

The peers or stocks similar to Lupin Ltd are Sun Pharmaceutical Industries Ltd, Cipla Ltd, Dr Reddy's Laboratories Ltd, Zydus Lifesciences Ltd and many others. smallcase also offers over 200 readymade stock baskets managed by 180+ SEBI-registered investment experts. These stock portfolios are based on a theme, idea or strategy. You can use smallcase to start investing in diversified stock baskets.

Which sector does Lupin Ltd belong to?

Lupin Ltd (LUPIN) belongs to the Pharmaceuticals sector.

What is the Market Cap of Lupin Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lupin Ltd (LUPIN) is ₹75,011 Cr as of 03 May 2024

Can't decide whether or not to buy Lupin Ltd stocks? ⭐️

Worry no more! smallcase offers readymade stock baskets/portfolios that are based on an theme, idea or strategy. You can choose from more than 500+ stock portfolios managed by 180+ SEBI-registered investment experts.

Dislaimer: This platform is intended for informational purposes only and is not intended to provide investment advice. The stock prices displayed are delayed and may not reflect the most current market conditions. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. You can also consider consulting a financial advisor before making any investment decisions. Smallcase Technologies Private Limited shall not be responsible for any losses that may occur as a result of using this platform.